Search

everythinglearnresearchcommunity

for

Search:↓

Baldness in men with prostate cancer is linked to higher levels of certain sex hormones, but chest hair density is not.

Combination therapy of doxazosin and finasteride safely and effectively reduces benign prostatic hyperplasia progression risk.

The document suggests that targeting the hormone DHT could be a more effective treatment for prostate cancer than targeting testosterone.

Antiandrogen drugs can reduce PSA levels in women with excess hair, suggesting PSA is a sign of male hormone activity in women.

The activity of a specific rat enzyme in the prostate and epididymis is highly dependent on the acidity level.

Male pattern baldness might have evolved to help protect against prostate cancer by increasing UV radiation on the scalp.

New steroids were effective in blocking male hormone receptors in hamster prostates.

A new compound was effective for imaging prostate cancer in rats.

Vertex baldness has higher DHT levels than frontal baldness, but testosterone and PSA levels are similar.

Finasteride can reduce prostate cancer risk but may delay diagnosis and cause sexual side effects.

Finasteride reduces bleeding during prostate surgery.

Opioid use may lower PSA levels, suggesting a possible role in prostate cancer control; PSA testing is useful for detecting prostate cancer; serum triglycerides are not linked to prostate cancer risk; and higher urethral PSA levels may be associated with local hormone activity.

The research found that androgens help control blood flow in the rat prostate through a specific binding site.

Finasteride reduces prostate cancer risk but may increase high-grade tumors; new drugs and better diagnosis are in development, but funding and industry commitment are challenges.

Hair loss, prostate size, and urinary issues are related due to androgen effects.

Prostate cancer prevention includes diet changes, supplements, and medications, with more answers expected soon.

5-α-reductase inhibitors reduce prostate cancer risk but may cause sexual dysfunction and don't affect high-grade tumor or death rates.

Men who experienced baldness at age 20 may have double the risk of getting prostate cancer.

Early-onset baldness is linked to a higher risk of aggressive prostate cancer in African-American men, especially before age 60.

Men with male pattern baldness have a higher risk of dying from prostate cancer.

Early balding at 40 increases prostate cancer risk.

Higher DHT in male baldness may protect against prostate cancer.

5-Alpha reductase inhibitors may prevent prostate cancer but are not widely used due to concerns about trial relevance and potential risks, and more research is needed to confirm long-term benefits.

Certain gene patterns in breast cancer are linked to how active hormone receptors are and could affect patient survival.

Baldness, especially at the front, may lower the risk of testicular cancer by 31%, but its link to prostate cancer is unclear.

Certain plasma proteins are linked to prostate cancer risk and could help in early detection and treatment.

A young man with high-grade prostate cancer had successful surgery and good recovery, highlighting the need for awareness in younger men.

Researchers developed promising agents for prostate cancer imaging, with the best one showing high potential for clinical use.

The conclusion suggests that prostate cancer should be classified by castration status and that new therapies targeting androgen receptor signaling show promise.

5-alpha-reductase inhibitors can lower prostate cancer risk but may increase high-grade tumors and cause sexual side effects.